EUVIMEDEUVIMED entdecken
Crossref

MicroRNA-9-5p targets ELAVL1 to regulate NLRP3 inflammasome activation and cardiomyocyte pyroptosis in diabetic hypoglycemic myocardial injury

Xiao Wei, Suxin Luo

Archives of Biochemistry and Biophysics · 2026-11 · 111055

DOI: 10.1016/j.abb.2026.111055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2026-11. Verfasst von Xiao Wei und 1 weiteren Autor:innen. Beteiligte Einrichtung: Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing, Chongqing, 402760, China. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Recurrent hypoglycemia during intensive glycemic control in diabetes is an independent risk factor for cardiovascular events and all-cause mortality, yet the molecular mechanisms underlying its myocardial damage remain poorly understood. This study aimed to investigate the role of post-transcriptional regulatory networks in diabetic recurrent hypoglycemic myocardial injury. METHODS: Type 2 diabetic mouse models were established using a high-fat diet combined with streptozotocin (STZ) injection, and recurrent hypoglycemia was induced by repeated insulin administration. Integrated mRNA-seq and small RNA-seq were performed to screen differentially expressed genes and microRNAs (miRNAs). Key upstream regulators of the NLR family pyrin domain containing 3 (NLRP3) inflammasome were identified via Pearson correlation analysis combined with predictions from the StarBase, TargetScan, and miRDB databases. Direct binding between miRNA and target gene was verified by dual-luciferase reporter assays. Gain- and loss-of-function experiments were conducted in a diabetic hypoglycemic HL-1 cardiomyocyte model by transfection with miR-9-5p mimics/inhibitor and ELAV-like protein 1 (ELAVL1)-targeting short hairpin RNA (sh-ELAVL1). In vivo intervention and rescue experiments were performed via tail vein injection of miR-9-5p agomir/antagomir and sh-ELAVL1 lentivirus. Myocardial structure and function were evaluated using echocardiography, hematoxylin-eosin (HE) staining, immunofluorescence, and Western blot. RESULTS: Mice with diabetic recurrent hypoglycemia exhibited significant weight loss (p < 0.001) and impaired cardiac function. Transcriptome analysis identified 42 differentially expressed genes between the diabetic (DM) and diabetic hypoglycemic (HDM) groups, with specific enrichment of the NOD-like receptor signaling pathway. Protein levels of NLRP3, cleaved caspase-1 (p20), and the N-terminal fragment of gasdermin D (GSDMD-N, p30) in the myocardium were further significantly upregulated in the HDM group compared with the DM group (p < 0.001). Correlation analysis combined with StarBase database screening identified ELAVL1 as the key upstream RNA-binding protein regulating NLRP3 (r = 0.82, p < 0.001). Small RNA sequencing revealed 16 significantly downregulated miRNAs in the HDM group versus the DM group. Intersection with TargetScan and miRDB predictions of ELAVL1-targeting miRNAs identified miR-9-5p as the sole candidate, which was significantly downregulated in the HDM group (p < 0.001). Dual-luciferase reporter assays confirmed direct binding of miR-9-5p to the 3' untranslated region (3'UTR) of ELAVL1 (p < 0.001). In vitro, transfection with miR-9-5p mimics significantly reduced the protein levels of ELAVL1, NLRP3, and cleaved caspase-1 (p < 0.001), increased cell viability, and decreased lactate dehydrogenase (LDH) release (p < 0.001). Conversely, miR-9-5p inhibitor promoted these pathological changes, which were fully reversed by sh-ELAVL1 (p < 0.001). In vivo, miR-9-5p agomir significantly improved left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) (both p < 0.01), inhibited co-localization of NLRP3 with apoptosis-associated speck-like protein containing a CARD (ASC), and downregulated the protein levels of GSDMD-N, interleukin-1β (IL-1β), and interleukin-18 (IL-18) (p < 0.001). miR-9-5p antagomir exacerbated these injuries, which were effectively reversed by co-administration of sh-ELAVL1 (p < 0.001). CONCLUSION: Our findings demonstrate that miR-9-5p directly targets ELAVL1 to inhibit NLRP3 inflammasome activation and cardiomyocyte pyroptosis, thereby attenuating myocardial injury and improving cardiac function in diabetic recurrent hypoglycemia. The miR-9-5p/ELAVL1/NLRP3 axis may represent a promising therapeutic target for diabetic hypoglycemic myocardial injury, although clinical validation of this axis in patients with diabetes remains to be performed.

Schlagwörter

Stichwörter der Autor:innen

Diabetic hypoglycemic myocardial injuryELAVL1MicroRNA-9-5pNLRP3 inflammasomePyroptosis

Autor:innen und Institutionen

  • Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing, Chongqing, 402760, China.
  • Department of Cardiology, Cardiovascular Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. Electronic address: luosuxin0623@163.com.

Zitieren

APA

Wei, X., & Luo, S. (2026). MicroRNA-9-5p targets ELAVL1 to regulate NLRP3 inflammasome activation and cardiomyocyte pyroptosis in diabetic hypoglycemic myocardial injury. Archives of Biochemistry and Biophysics, 111055. https://doi.org/10.1016/j.abb.2026.111055

Vancouver

Wei X, Luo S. MicroRNA-9-5p targets ELAVL1 to regulate NLRP3 inflammasome activation and cardiomyocyte pyroptosis in diabetic hypoglycemic myocardial injury. Archives of Biochemistry and Biophysics. 2026:111055. doi:10.1016/j.abb.2026.111055

BibTeX
@article{Wei2026,
  author = {Wei, Xiao and Luo, Suxin},
  title = {MicroRNA-9-5p targets ELAVL1 to regulate NLRP3 inflammasome activation and cardiomyocyte pyroptosis in diabetic hypoglycemic myocardial injury},
  journal = {Archives of Biochemistry and Biophysics},
  year = {2026},
  pages = {111055},
  doi = {10.1016/j.abb.2026.111055}
}
Kostenlos starten →